ARK Genomic Revolution ETF
ARKG
5 hedge funds and large institutions have $586K invested in ARK Genomic Revolution ETF in 2016 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
282% more capital inflows, than outflows
Capital inflows: $46.8K | Capital outflows: $12.3K
7.51% more ownership
Funds ownership: 0% → 7.51% (+7.5%)
0% more funds holding
Funds holding: 5 → 5 (0)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$46.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$12.3K |
ARKG Hedge Fund Activity: Q4 2016 in Review
5 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q4 2016, worth a combined $586K — down 9.6% from $648K a quarter earlier.
Fund positioning in ARKG was balanced in Q4 2016: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Jane Street, adding an estimated $46.8K. The largest seller was UBS Group, cutting an estimated $12.3K.
- 5 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q4 2016, unchanged from Q3 2016.
- Funds reported $586K of ARK Genomic Revolution ETF stock for Q4 2016, down 9.6% quarter-over-quarter.
- 0 funds opened new ARK Genomic Revolution ETF positions in Q4 2016 and 0 closed out.
- The largest ARK Genomic Revolution ETF buyer in Q4 2016 was Jane Street, an estimated $46.8K added.
- The largest ARK Genomic Revolution ETF seller in Q4 2016 was UBS Group, an estimated $12.3K sold.
Based on aggregated 13F filings for Q4 2016.